α-Synuclein-induced synapse damage in cultured neurons is mediated by cholesterol-sensitive activation of cytoplasmic phospholipase A2

Biomolecules
Clive Bate, Alun Williams

Abstract

The accumulation of aggregated forms of the α-synuclein (αSN) is associated with the pathogenesis of Parkinson's disease (PD) and Dementia with Lewy Bodies. The loss of synapses is an important event in the pathogenesis of these diseases. Here we show that aggregated recombinant human αSN, but not βSN, triggered synapse damage in cultured neurons as measured by the loss of synaptic proteins. Pre-treatment with the selective cytoplasmic phospholipase A2 (cPLA2) inhibitors AACOCF3 and MAFP protected neurons against αSN-induced synapse damage. Synapse damage was associated with the αSN-induced activation of synaptic cPLA2 and the production of prostaglandin E2. The activation of cPLA2 is the first step in the generation of platelet-activating factor (PAF) and PAF receptor antagonists (ginkgolide B or Hexa-PAF) also protect neurons against αSN-induced synapse damage. αSN-induced synapse damage was also reduced in neurons pre-treated with the cholesterol synthesis inhibitor (squalestatin). These results are consistent with the hypothesis that αSN triggered synapse damage via hyperactivation of cPLA2. They also indicate that αSN-induced activation of cPLA2 is influenced by the cholesterol content of membranes. Inhibitors of this path...Continue Reading

References

Sep 1, 1995·Journal of Neurochemistry·D C CrickC J Waechter
Aug 1, 1997·Journal of Neuropathology and Experimental Neurology·C I SzeL J Martin
Dec 1, 1998·Journal of Neurochemistry·P KlivenyiJ V Bonventre
Nov 11, 1999·Proceedings of the National Academy of Sciences of the United States of America·J E GalvinJ Q Trojanowski
Jun 20, 2001·Nature Reviews. Molecular Cell Biology·K Simons, D Toomre
Dec 25, 2002·Neurobiology of Aging·Heiko BraakEva Braak
Mar 14, 2003·Archives of Neurology·Dag AarslandPer Kragh-Sørensen
Dec 6, 2003·Journal of Lipid Research·Grace Y SunAgnes Simonyi
Dec 10, 2003·The Biochemical Journal·Linda J Pike
Oct 16, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Badreddine KriemThierry Pillot
Oct 21, 2005·Neurology·I G McKeithUNKNOWN Consortium on DLB
Nov 5, 2005·Cell·Nancy M Bonini, Benoit I Giasson
Nov 9, 2005·The Journal of Clinical Investigation·Matthew J BellizziHarris A Gelbard
Dec 2, 2005·Nature·Frederick R Maxfield, Ira Tabas
Mar 8, 2006·Brain Research·Maria Emília ThaisCarla I Tasca
May 11, 2006·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Akhlaq A Farooqui, Lloyd A Horrocks
Feb 9, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Michael L Kramer, Walter J Schulz-Schaeffer
Mar 3, 2007·The Journal of Biological Chemistry·Yukihiko Sugimoto, Shuh Narumiya
Jan 9, 2008·Molecular Neurodegeneration·Clive BateAlun Williams
Jan 11, 2008·Neurology·Angelika D WahnerBeate Ritz
Apr 11, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·W Poewe
Apr 11, 2008·Neurology·G HuJ Tuomilehto
Oct 1, 2008·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Ali SamiiMahyar Etminan
Oct 22, 2008·Nature Neuroscience·Rene O Sanchez-MejiaLennart Mucke
Dec 10, 2008·Archives of Neurology·Aleksey G Kazantsev, Alexander M Kolchinsky
Mar 20, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Chee Yeun ChungOle Isacson
Apr 16, 2009·Expert Opinion on Drug Safety·Claudia Becker, Christoph R Meier
Aug 5, 2009·Proceedings of the National Academy of Sciences of the United States of America·Paula DesplatsSeung-Jae Lee
Mar 24, 2010·Nature Reviews. Molecular Cell Biology·Patrik BrundinRon Kopito
Apr 9, 2010·Molecular Neurodegeneration·Clive BateAlun Williams
Nov 30, 2010·Experimental Neurology·Amalia M DolgaUlrich L M Eisel
Dec 9, 2010·Molecular Neurodegeneration·Clive BateAlun Williams
Sep 9, 2011·The Journal of Biological Chemistry·Clive Bate, Alun Williams

❮ Previous
Next ❯

Citations

Nov 15, 2016·Expert Opinion on Therapeutic Patents·Henryk JęśkoAgata Adamczyk
Jan 10, 2019·Cells·Helena XicoyGerard J M Martens
Sep 16, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Mary XylakiEvangelia Emmanouilidou
Apr 23, 2019·Journal of Neurochemistry·Luan Pereira DinizFlávia Carvalho Alcantara Gomes
May 31, 2018·Journal of Alzheimer's Disease : JAD·Oluwatomi E S AkingbadeElizabeta B Mukaetova-Ladinska
Jun 22, 2018·Neural Regeneration Research·Wen-Juan FanJie-Xin Deng
Dec 11, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ronan LordanConstantinos A Demopoulos
Dec 29, 2020·Prostaglandins & Other Lipid Mediators·Barbara DalmasoCarolina Beltrame Del Debbio
Sep 1, 2020·Archives of Gerontology and Geriatrics·Soumyabrata Banerjee, Mrinal K Poddar
Apr 7, 2021·The Journal of Pharmacy and Pharmacology·Tanvi Dayanand Pingale, Girdhari Lal Gupta

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
PLAP
ELISA
protein assay

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Alpha-Synuclein Aggregation

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.